Blenderized food tube feeding in patients with head and neck cancer

Amy Y. Spurlock PhD, RN1 | Teresa W. Johnson DCN, RDN2 | Ali Pritchett RDN3
Leah Pierce RDN3 | Jenna Hussey DNP, RN1 | Kelly Johnson DNP, RN1
Holly Carter PhD, RN1 | Stephen L. Davidson MD4 | Manpreet S. Mundi MD5
Lisa Epp RDN6 | Ryan T. Hurt MD, PhD7

1 School of Nursing, Troy University, Troy, Alabama, USA
2 College of Health and Human Services, Troy University, Troy, Alabama, USA
3 Montgomery Cancer Center, Montgomery, Alabama, USA
4 Alabama Oncology Hematology Associates at The Montgomery Cancer Center, Montgomery, Alabama, USA
5 Division of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA
6 Endocrinology, Mayo Clinic Rochester, Rochester, Minnesota, USA
7 Medicine, Mayo Clinic, Rochester, Minnesota, USA

Correspondence
Teresa W. Johnson, DCN, RDN, 107A Wright Hall, Troy University, Troy, Alabama 36081, USA.
E-mail: tjohnson@troy.edu

Funding information
Real Food Blends provided blenderized tube feeding product.

Abstract
Background: Patients with head and neck cancer (HNC) are at high risk for malnutrition before and during chemoradiation treatment. Many will also require tube feeding to address declines in energy intake, weight, and quality of life (QOL) caused by the impact of treatment on gastrointestinal (GI) symptoms. Blenderized tube feeding (BTF) may ameliorate these adverse conditions.

Methods: In this open-label, prospective pilot study, 30 patients with HNC who required feeding tube placement were recruited to switch from standard commercial formula after 2 weeks to a commercially prepared BTF formula. Weight, body mass index (BMI), GI symptoms, and QOL scores were tracked for 6 weeks from the first week of feeding tube placement.

Results: Of the 16 patients who completed the 6-week assessment period, weights and BMI scores for 15 patients trended upward. For most patients, QOL and oral intake increased and GI symptoms decreased over the 6-week period, particularly during weeks 3 and 4, when the impact of treatment is particularly exacting on patients with HNC.

Conclusion: BTF effectively mitigated weight loss, GI symptoms, QOL scores, and total energy intake in this group of patients with HNC who received tube feeding for 6 weeks.

Keywords
blenderized tube feeding, enteral nutrition, head and neck cancer, malnutrition, quality of life

INTRODUCTION

Cancer is the second leading cause of death in the United States, resulting in about 1700 deaths each day. Specifically, the incidence of head and neck cancer (HNC) has spiked globally in the last 15 years, including a 26% increase in stage IV HNC cases in the United States—particularly among males. HNC patients are at a high risk for malnutrition, as they frequently experience dysphagia, dysgeusia, mucositis, xerostomia, anorexia, nausea, and vomiting caused by multiple treatment toxicities. Tumor burden, the catabolic and systemic inflammatory nature of cancer,
alterations in digestion and absorption, adverse effects of treatments, and postoperative recovery further exacerbate nutrition risks in this population. Although malnutrition occurs in 40%–80% of cancer patients during treatment, up to 60% of HNC patients may be malnourished at the time of diagnosis. Nutrition counseling and oral nutrition supplements are the first line of treatment, but HNC patients frequently require enteral nutrition support at some point during treatment intervention. Enteral tube feeding is recommended when oral intake is <60% of the estimated need for an anticipated or actual >10 days or when a patient is unable to maintain weight. Some healthcare providers (HCPs) recommend feeding tube placement prior to treatment or prior to the development of swallowing problems to prevent malnutrition. Unfortunately, weight loss is common in HNC patients, with nearly 60% reporting significant weight loss (≥10%) regardless of prophylactic or reactive tube feeding approaches to prevent malnutrition.

This is largely a result of poor adherence to feeding recommendations because of nausea and early satiety. Significant weight loss is an independent predictor of survival.

Although commercial formula (CF) is the predominant tube feeding substrate recommended by HCPs, increased interest and use of blended tube feeding (BTF) has emerged in recent years, largely because of patient and caregiver demands as well as HCP interest. Evidence of reduced tube feeding intolerance (gagging, retching, constipation, diarrhea, and abdominal pain), reduced hospital admissions, and reduced need for gastrointestinal (GI) medications is reported in pediatric populations utilizing BTF. Furthermore, these investigations confirm that BTF supports growth and weight goals. Studies in adult populations are scant, but early evidence suggests favorable outcomes, including reduced diarrhea and weight loss prevention.

These outcomes are consistent whether full or partial BTF is used for nutrition support. One retrospective chart-review study reported negative outcomes of BTF in adult HNC patients, but the investigation lacked a true control group.

Given that the majority of BTF studies demonstrate success in ameliorating GI issues and support weight goals, prospective BTF investigations are warranted in the HNC population, in which these issues are especially problematic. The purpose of this open-label, prospective pilot study was to explore the impact of a BTF (full or partial) on GI symptoms, selected anthropometric variables, the ability to meet tube feeding goals, and quality of life (QOL) in patients with HNC who required tube feeding during their treatment. In order to account for any effect of sustained treatment and disease progression, comparisons were planned for three intervals: (1) initial 2 weeks receiving CF, followed by (2) 3 weeks receiving BTF (full or partial), followed by (3) 2 weeks back to 100% CF.

**METHODS**

The institutional review boards (IRBs) of the university that employs the researchers as well as the medical facility approved the study. Registered dietitians/nutritionists (RDNs) working at an outpatient cancer treatment center recruited participants (adults ≥19 years old) with HNC who required gastric feeding tube placement at the time they began radiation and chemotherapy treatments. Patients were given detailed instructions about the study and signed consent forms if they agreed to participate. The recruitment period began on March 1, 2019 with a goal of 30 patients completing the study within 1 year. Reaching the goal of 30 participants was difficult because of the onset of the coronavirus disease 2019 (COVID-19) pandemic and the variable nature of HNC patient treatment experiences (eg, hospitalization, death, shorter period of time needed for tube feeding than anticipated, etc).

At the initiation of gastric feeding tube placement, RDNs performed nutrition-focused physical exams and patients completed baseline questionnaires on GI symptoms and QOL. Patients also completed weekly logs. Collection tools were developed by the Mayo Clinic, Rochester, MN, USA. Specific anthropometric variables of interest, collected weekly by the RDNs throughout the study, were weight, body mass index (BMI), and fat-free mass (FFM) using a bioelectrical impedance scale (Tanita SC-331S, Chicago, IL, USA) and a portable stadiometer (Seca Model 0123, Chino, CA, USA).

Patients for whom swallowing was deemed safe were encouraged to eat food by mouth in addition to tube feeding administration, but RDNs estimated most nutrient needs were likely to be provided solely by tube feeding based on previous experiences with this population. Patients were provided with standard CF for the first 2 weeks of the study, and baseline anthropometric data and data on GI symptoms were collected. Patients began completing the weekly tube feeding log, and RDNs collected anthropometric data during weekly interactions with patients throughout the entire study.

After 2 weeks receiving 100% CF tube feeding, patients completed a pre-BTF Patient Satisfaction Survey and the symptoms-only portion of the Weekly BTF Log. The BTF Log consists of six questions: the number of days per week that BTF was used; the percent of total calorie intake of BTF; whether supplements, food, or beverages were consumed; what symptoms were experienced; whether the feeding tube became clogged; and additional comments.

The RDNs then instructed patients to replace half of their CF prescription with a commercially prepared BTF product (Real Food Blends, Chesterton, IN, USA). The partial BTF period was to last for 3 weeks with weekly data collection continued. At the end of the 3 weeks receiving
TABLE 1 Reasons for Noncompletion

| Reasons for noncompletion                          | Number | Percent |
|---------------------------------------------------|--------|---------|
| Prolonged hospitalization/death                   | 4      | 28.5    |
| Caregiver/situational noncompliance               | 3      | 21.4    |
| PEG tube removed/leaking with bolus feeds         | 2      | 14.2    |
| Treatment changed to continuous feeds only because of COVID-19 scheduling | 2 | 14.2 |
| Inconvenience (did not want to mix with water)    | 2      | 14.2    |
| Stopped all treatment                             | 1      | 7.1     |

Abbreviations: COVID-19, coronavirus disease 2019; PEG, percutaneous endoscopic gastrostomy.

Because of the small sample size, inferential statistics were not conducted. Of the 30 participants who enrolled in the study, 16 (53.3%) completed it. Out of the 14 who enrolled but did not complete it, four (28.5%) never began BTF. However, of the 10 participants who began BTF but did not complete the study, nine (90%) tolerated BTF. Treatment started for 16 (53.3%) of the 30 participants. Only one participant (#030) began the study with a BMI score below 18.5 (indicating underweight), but that participant maintained their BMI score of 15.8 at the end of the study (Figure 2). The mean BMI score decreased from 23.75 (SD = 4.13) in week 1 to 22.79 (SD = 3.89) in week 6.

Symptoms over time are displayed in Table 4. Overall, all symptoms improved while patients received BTF, including pain (18.8% to 12.5%), vomiting (31.3% to 12.5%), constipation (31.3% to 12.5%), gas/bloating (50% to 18.8%), nausea (62.5% to 12.5%), and diarrhea (37.5% to 0%). Additionally, “other symptoms” decreased from six patients reporting to zero patients reporting.

Table 3 displays the results of the BMI over time. BMI scores improved or held steady for 10 (56.5%) of the 16 participants. Only one participant (#030) began the study with a BMI score below 18.5 (indicating underweight), but that participant maintained their BMI score of 15.8 at the end of the study (Figure 2). The mean BMI score decreased from 23.75 (SD = 4.13) in week 1 to 22.79 (SD = 3.89) in week 6.

Table 2 displays the results of weight over time of the 16 participants. A comparison was made of the weight loss percentage from baseline to the end of BTF using a 1-month criteria (5%). Only two patients (12.5%) experienced significant weight loss, but one participant experienced weight trending upward after BTF was initiated. A patient (#012) continued to lose weight over time. The percent caloric intake increased from 0% to 18.8% to 25%, respectively. The number of patients reporting supplements remained steady, but the 3 weeks receiving BTF, patients reported an increased intake of solid foods from 50% to 77.7%. Only two patients in week 1 (12.5%), two patients in week 2 (12.5%), and one patient in week 3 (6.1%) reported clogging in the feeding tube; this was primarily related to the beef and egg flavors, which had a higher viscosity. Patients reported that the clogged tubes did not require intervention, just manipulation of the tube. The comments related to BTF remained positive throughout the study.

QOL before tube feeding, before the initiation of BTF, and after the initiation of BTF is found in Table 6. Those reporting bad or very bad QOL decreased from 6 (37.6%) before tube feeding was initiated to 3 (8.8%) while receiving CF before BTF to zero after BTF was initiated. Those reporting a good or very good QOL increased from 6 (50.1%) before BTF initiated to 15 (91.3%) after BTF was initiated. Additionally, 14 (87.6%) patients disagreed or strongly disagreed with the statement, “BTF added stress to my life,”
| ID  | Week 1, lbs/kg | Week 2, lbs/kg | Week 3, lbs/kg | Week 4, lbs/kg | Week 5, lbs/kg | Week 6, lbs/kg | Change, % |
|-----|---------------|---------------|---------------|---------------|---------------|---------------|-----------|
| 001 | 188 (85.45)   | 190 (86.36)   | 189.4 (86.09) | 188.2 (85.54) | 189.2 (86.0)  | 189 (85.9)    | +0.53     |
| 002 | 197.8 (89.9)  | 184 (83.63)   | 181 (82.27)   | 178 (80.9)    | 179.6 (81.63) | 184.4 (83.81) | −6.77     |
| 007 | 147.2 (66.9)  | No data       | 144 (65.45)   | 146.6 (66.63) | 148.0 (67.27) | 150.6 (68.45) | +2.2      |
| 011 | 150.8 (68.54) | 149.2 (67.81) | 147.2 (66.9)  | 149.2 (67.81) | 152.4 (69.27) | 151.2 (68.72) | +0.26     |
| 012 | No data       | 152.8 (69.45) | No data       | 143.8 (65.36) | 139.4 (63.36) | 134.8 (61.27) | −11.7     |
| 014 | 170.4         | 169.2 (76.9)  | No data       | 163.8 (74.45) | 161.6 (73.45) | 158.2 (71.9)  | −7.15     |
| 015 | 160.8         | 159.8 (72.63) | No data       | 158.4 (72.0)  | No data       | 154.8 (70.36) | −3.73     |
| 016 | 148.6         | No data       | 114.4 (52.0)  | 125.6 (57.09) | No data       | 132.2 (60.09) | −11.0     |
| 017 | 138.6         | 135.0 (61.36) | 134.9 (61.31) | 131.0 (59.54) | 127.0 (57.72) | 130.0 (59.09) | −6.2      |
| 019 | No data       | No data       | 164.0 (74.54) | 162.0 (73.63) | 161.0 (73.18) | 157.6 (78.8)  | −0.39     |
| 024 | 114.8         | No data       | 111.4 (52.0)  | 110.8 (50.36) | No data       | 120.2 (54.63) | +4.5      |
| 025 | 228.2         | 230.0 (104.54)| No data       | 227.0 (103.18)| 226.8 (103.4)| 227.0 (103.18)| −0.52     |
| 026 | 111.8         | 113.80 (51.72)| 113.80 (51.72)| 108.80 (49.45)| 114.0 (51.81)| 118.60 (53.90)| +5.7      |
| 028 | 152.6         | 152.6 (69.36) | No data       | 148.80 (67.63)| 146.8 (66.72)| 151.80 (69.0) | +0.52     |
| 029 | 169.2         | 172.0 (86.0)  | No data       | 173.8 (79.0)  | 175.8 (79.9)  | 174.00 (79.09)| +2.7      |
| 030 | No data       | 98.0 (49.0)   | No data       | No data       | No data       | 97.60 (44.36) | −0.40     |
| Mean| 159.98        | 158.56 (72.07)| 144.45 (65.65)| 154.38 (70.17)| 160.13 (74.6) | 152.0 (69.09) |           |
| SD  | 32.06         | 35.04         | 29.09         | 30.58         | 30.08         | 31.48         |           |

**Table 2** Weight of participants over time

**Figure 1** Mean weight of participants over time
### TABLE 3  Body mass index score of participants over time

| ID   | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Change, % |
|------|--------|--------|--------|--------|--------|--------|-----------|
| 001  | 24.4   | 24.7   | 24.6   | 24.5   | 24.6   | 24.6   | +0.8      |
| 002  | 28.4   | 26.5   | 26     | 25.5   | 24.36  | 26     | −3.5      |
| 007  | 19.4   | No data| 18.9   | 19.3   | No data| 19.9   | +2.5      |
| 011  | 25.09  | 25.6   | 25.3   | 25.6   | 26.2   | 26     | +3.5      |
| 012  | No data| 22.6   | No data| 20.9   | 20.6   | 19.9   | −11.9     |
| 014  | 24.8   | 23.6   | No data| 23.8   | 23.4   | 23     | −7.2      |
| 015  | 28.5   | 28.3   | No data| 28.1   | No data| 27.4   | −3.8      |
| 016  | 25.9   | No data| 19.9   | 21.9   | No data| 23.4   | −9.6      |
| 017  | 19.97  | 19.40  | 19.40  | 18.87  | 18.30  | 18.65  | −6.6      |
| 019  | No data| No data| 26.50  | 25.80  | 26.00  | 25.40  | −4.1      |
| 024  | 18.2   | No data| 17.7   | 17.6   | No data| 19.1   | +4.7      |
| 025  | 31.40  | 31.60  | No data| 31.20  | 31.20  | 31.20  | −0.63     |
| 026  | 18.90  | 19.20  | 19.20  | 18.40  | 19.20  | 20.00  | +5.5      |
| 028  | 22.2   | No data| No data| 21.70  | 21.4   | 22.10  | −0.4      |
| 029  | 21.70  | 22.10  | 22.30  | 22.60  | No data| 22.30  | +2.6      |
| 030  | No data| 15.8   | No data| No data| No data| 15.80  | 0         |
| Mean | 23.75  | 23.77  | 21.94  | 23.03  | 23.11  | 22.79  |           |
| SD   | 4.13   | 4.32   | 3.55   | 3.83   | 3.66   | 3.89   |           |

**FIGURE 2**  Mean BMI of participants over time. BMI, body mass index
and 15 (92.7%) disagreed or strongly disagreed with the statement, “BTF overwhelmed my caretaker.”

**DISCUSSION**

The results of this prospective, open-label pilot study of BTF in HNC patients requiring tube feeding during chemoradiotherapy resulted in positive outcomes, particularly the impacts on weight, GI symptoms, and QOL. These findings are consistent with other published work in adult populations comparing BTF with CF, with one exception. In a retrospective chart analysis, Papakostas et al. compared BMI and FFM (measured by bioelectrical impedance analysis) between BTF- and CF-fed HNC patients receiving home enteral nutrition at the time of tube placement, 8 weeks after chemoradiotherapy treatment ended, and 6 months after treatment ended. They reported the BTF group experienced significant declines in BMI and FFM, but the CF (n = 112) group almost reached levels measured at initial diagnosis. However, both the BTF and CF groups were instructed to consume yogurt, honey, ice cream, and fruit and vegetable juices through their tubes or orally each day. Furthermore, the BTF group (n = 31) lacked insurance and was given a recipe to follow, but follow-up and continued oversight on the feeding was not provided. Also, the original number in the CF group was 181, but 69 patients opted to stop taking the insurance-provided formula during the 8-week follow-up period and made their own BTF, again, with no oversight from HCPs. The lack of a true control group and the disparity in nutrition oversight of the three feeding substrates make it difficult to draw

---

**TABLE 4** Symptoms of participants over time

| | CF final week, n (%) | BTF week 1, n (%) | BTF week 2, n (%) | BTF week 3, n (%) |
|---|---|---|---|---|
| **Nausea** | | | | |
| Yes | 10 (62.5) | 7 (43.8) | 7 (43.8) | 2 (12.5) |
| No | 6 (37.5) | 6 (37.5) | 7 (43.8) | 11 (68.8) |
| Missing | 3 (18.8) | 2 (12.5) | 3 (18.8) | |
| **Vomiting** | | | | |
| Yes | 5 (31.3) | 6 (37.5) | 7 (43.8) | 2 (12.5) |
| No | 11 (68.8) | 7 (43.8) | 7 (43.8) | 11 (68.8) |
| Missing | 3 (18.8) | 2 (12.5) | 3 (18.8) | |
| **Fever** | | | | |
| Yes | 0 (0) | 1 (6.3) | 1 (6.3) | 2 (12.5) |
| No | 16 (100) | 12 (75.0) | 13 (81.3) | 11 (68.8) |
| Missing | 3 (18.8) | 2 (12.5) | 3 (18.8) | |
| **Gas/bloating** | | | | |
| Yes | 8 (50.0) | 2 (12.5) | 1 (12.5) | 3 (18.8) |
| No | 8 (50.0) | 11 (68.8) | 12 (75.0) | 10 (62.5) |
| Missing | 3 (18.8) | 2 (12.5) | 3 (18.8) | |
| **Diarrhea** | | | | |
| Yes | 6 (37.5) | 4 (25.0) | 4 (25.0) | 0 (0) |
| No | 10 (62.5) | 9 (55.3) | 10 (62.5) | 13 (81.3) |
| Missing | 3 (18.8) | 2 (12.5) | 3 (18.8) | |
| **Constipation** | | | | |
| Yes | 5 (31.3) | 4 (25.0) | 5 (31.3) | 2 (12.5) |
| No | 10 (68.8) | 9 (56.3) | 9 (56.3) | 11 (68.8) |
| Missing | 3 (18.8) | 2 (12.5) | 3 (18.8) | |
| **Pain** | | | | |
| Yes | 3 (18.8) | 3 (18.8) | 3 (18.8) | 2 (12.5) |
| No | 13 (81.3) | 10 (62.5) | 11 (68.8) | 11 (68.8) |
| Missing | 3 (18.8) | 2 (12.5) | 3 (18.8) | |
| **Other symptoms** | | | | |
| Heartburn, indigestion, reflux, tinnitus, arm and back pain, and sore throat | Sore throat and pain at cancer site | N and V with Osmolite only, N and V with salmon flavor, and pain at cancer site | None | |

Abbreviations: BTF, blended tube feeding; CF, commercial formula; N, ; V, .
TABLE 5  BTF log over time

| Days per week/BTF | BTF week 1, n (%) | BTF week 2, n (%) | BTF week 3, n (%) |
|-------------------|-------------------|-------------------|-------------------|
| 1                 | 0 (0)             | 1 (6.3)           | 0 (0)             |
| 2                 | 0 (0)             | 0 (0)             | 1 (6.3)           |
| 3                 | 1 (6.3)           | 1 (6.3)           | 1 (6.3)           |
| 5                 | 1 (6.3)           | 0 (0)             | 1 (6.3)           |
| 7                 | 9 (56.3)          | 12 (75.0)         | 10 (62.5)         |
| Missing           | 5 (31.3)          | 2 (12.5)          | 3 (18.8)          |

| Caloric intake/BTF, % | Before BTF initiated, n (%) | After BTF initiated, n (%) |
|-----------------------|-----------------------------|---------------------------|
| 0–25                  | 2 (12.5)                    | 1 (6.3) (31.3)            |
| 26–50                 | 6 (37.5)                    | 5 (31.3)                  |
| 51–75                 | 3 (18.8)                    | 4 (25.0)                  |
| 76–100                | 0 (0)                       | 3 (18.8)                  |
| Missing               | 5 (31.3)                    | 2 (12.5)                  |

| Supplements | Before BTF initiated, n (%) | After BTF initiated, n (%) |
|-------------|-----------------------------|----------------------------|
| Yes         | 8 (50.0)                    | 7 (43.8)                   |
| No          | 3 (18.8)                    | 6 (37.5)                   |
| Missing     | 5 (31.3)                    | 3 (18.8)                   |

| Type supplements | Before BTF initiated, n (%) | After BTF initiated, n (%) |
|------------------|-----------------------------|---------------------------|
| Food             | 4 (50.0)                    | 7 (77.7)                  |
| Boost/Ensure     | 2 (12.5)                    | 0 (0)                     |
| Water/liquids    | 2 (12.5)                    | 2 (22.2)                  |

| Tube clogged     | Before BTF initiated, n (%) | After BTF initiated, n (%) |
|------------------|-----------------------------|---------------------------|
| Yes              | 2 (12.5)                    | 1 (6.3)                   |
| No               | 8 (50.0)                    | 12 (75.0)                 |
| Missing          | 6 (37.5)                    | 2 (12.5)                  |

| Comments | Before BTF initiated, n (%) | After BTF initiated, n (%) |
|----------|-----------------------------|---------------------------|
| “BTF is pleasant” | 1 (6.3)                    | 0 (0)                     |
| “I feel full (haven’t felt in a long time)”; “Clogs with BTF beef flavor only”; “The product is very beneficial to me” | 1 (6.3) | 0 (0) |
| “Clogs with egg blend only”; “It (BTF) saved my life”; “BTF takes a little longer but I don’t mind because it improved my symptoms” | 5 (31.3) | 10 (60.0) |

Abbreviation: BTF, blenderized tube feeding.

TABLE 6  Presurvey and postsurvey results for quality of life

| Quality of life | Before tube feeding initiated, n (%) | Before BTF initiated, n (%) | After BTF initiated, n (%) |
|-----------------|--------------------------------------|-----------------------------|---------------------------|
| Very bad        | 1 (6.3)                              | 1 (6.3)                     | 0 (0)                     |
| Bad             | 5 (31.3)                             | 2 (12.5)                    | 0 (0)                     |
| Neutral         | 1 (6.3)                              | 5 (31.3)                    | 1 (6.3)                   |
| Good            | 5 (31.3)                             | 7 (43.8)                    | 10 (60.0)                 |
| Very good       | 4 (25.0)                             | 1 (6.3)                     | 5 (31.3)                  |

Abbreviation: BTF, blenderized tube feeding.

conclusions on the efficacy of BTF in HNC patients from this study.

For 6 weeks, Pandit et al tracked the weight of 357 HNC patients who were beginning active chemoradiotherapy treatment. The sample included patients who received CF tube feeding and those who were fed orally. Overall, 67.4% experienced a mean weight loss >5%, and 28.8% of the participants lost >10% of their weight over 6 weeks. They observed that maximal weight loss began at week 3 and continued through week 6. These observations are consistent with other published work showing that most HNC patients experience difficulty with eating and subsequent declines in weight during weeks 3–4 of treatment that persist after treatment’s end. In contrast, our results demonstrated that BTF promoted weight increase for all except one patient, similar to the results of Hurt et al.25
Furthermore, maximal mean weight loss experienced at the end of week 3 began to rebound at week 4; 2 weeks after the introduction of BTF to their diets. The weight rebound occurred during the time that participants increased the proportion of BTF in their total intake. Similarly, Hurt et al. noted that BTF use and weight increased over their 6-week study. The potential impact of BTF on arresting significant weight loss at this critical point in care has implications beyond the treatment period.

The favorable impact of BTF on reducing adverse GI symptoms in children is well documented. At least two studies on the impact of BTF for reducing adverse GI symptoms in adults have been published. In an observational study, Fabiani et al. compared diarrhea occurrence between two groups of critically ill patients in a cardiac intensive care unit. Both groups were tube fed, but one group (n = 103) received a BTF prepared by hospital staff and delivered by syringe bolus three times a day. The other group (n = 112) received a standard CF delivered by continuous pump infusion for 15 h per day. During the 8-day observation, 48.2% of the CF group developed diarrhea compared with 27.2% of the BTF group, demonstrating a significantly lower probability of diarrhea occurrence in BTF use (P = .023).

In a multicenter, open-label, randomized controlled trial, Schmidt et al. followed 118 critically ill neurological patients (e.g., stroke, traumatic brain injury, etc.) for 30 days who required tube feeding. Half the group was fed reconstituted CF and the other half was fed a commercially prepared BTF; both feeds were delivered by pump. Both groups maintained their average BMI of 25. The BTF group had a significantly reduced number of watery stools and fewer days with diarrhea.

Similarly, participants in our study reported reductions in pain, vomiting, gas/bloating, nausea, and constipation, and the incidence of diarrhea, specifically, declined from 37.5% to 0% from the period ending CF to the period ending BTF. During this time period, patients were able to increase the proportion of BTF, the intake of solid food and supplements by mouth, and the overall calorie intake. These results are remarkable in that they occurred during the time that HNC patients typically experience declines in oral feeding and weight along with increased reports of GI symptoms. Concurrent with improved GI function, patients in our study reported improved QOL scores after tube feeding was initiated, but more so when they were switched from CF to BTF. Mulasi et al. noted that QOL scores declined as malnutrition scores increased in their study of outpatients with HNC; this is consistent with other work showing >10% weight loss is positively correlated with declining QOL scores. Preventing nutrition decline has important implications for psychosocial care of patients with HNC.

The rationale behind the efficacy of BTF has not been clearly elucidated. However, the contribution of dietary variety from whole foods (e.g., phytoneutrients) is associated with an improved intestinal microbiome; this is demonstrated in two studies of BTF in children. High-fiber diets selectively increase the growth of beneficial bacteria that, in turn, reduce infection from enteropathogens. Real food provides prebiotics and probiotics that maintain a favorable microbiome in the gut. Conversely, standard CF is a highly processed, monotonous feeding substrate consisting mostly of corn syrup solids, corn maltodextrins, soy and casein proteins, and various ratios of different types of fats/oils and micronutrient mixtures.

Another point to consider is the psychosocial dynamic of BTF. Resurgence of BTF interest and use has been largely patient and caregiver driven. Although many initiate BTF to address tube feeding intolerance, a significant number elect BTF because it represents a more physiologic feeding. This perspective aligns with the lifestyle recommendations from the American Institute of Cancer Research (AICR) Third Expert Reports, which include eating a diet rich in whole grains, vegetables, fruits, and beans and limited consumption of processed and red meat, sugar-sweetened beverages, and alcohol during and after cancer treatment. Multiple studies of cancer survivors demonstrate that following a healthy diet reduces overall mortality by 22%, but eating a typical Western diet of highly processed foods increases the risk of death by 51%. Unfortunately, the diet quality of cancer survivors is rather low, with a Healthy Eating Index score of 55.6 (out of a potential 100 points). Utilizing BTF may serve a twofold purpose: to reduce the adverse effects and poor outcomes associated with HNC treatments and to provide a teachable moment convincing patients that following AICR diet recommendations after treatment also confers benefit. Our study results are consistent with other studies demonstrating increased oral intake with BTF use; this teachable moment may present itself during those critical weeks when tube feeding is needed during chemoradiation therapy.

Many patients make their own BTF using a variety of resources, and the CF industry has responded to consumer demand with the introduction of several prepackaged BTF products. However, HCPs have not been as enthusiastic about BTF, citing concerns of the risk of microbial contamination and subsequent infection, clogged tubes, and unknown or inconsistent nutrient composition. Ironically, in spite of these concerns, HCPs have rarely, if ever, experienced them in clinical practice. Furthermore, recent studies demonstrate acceptable microbial loads of hospital- and home-prepared BTF compared with earlier studies conducted in conditions of unknown or unacceptable safe food-handling.
The addition of BTF.25 Despite the difficulties of conduct-
3–4 in HNC chemoradiation therapy were reversed with
weight loss and declining QOL scores typical of weeks
Hurt et al are of particular importance because, in both,
they do support existing papers on the efficacy of BTF
Although the results of this pilot study are not generaliz-
tions.38,39 The insistence that tube-fed patients be
given sterile product may needlessly prohibit them from
the benefits of foodborne nonpathogenic bacteria avail-
able in whole-food mixtures.37 Studies that show poor
weight and/or growth outcomes when BTF is used may be
biased by other factors, such as disparate socioeconomic
conditions impacting healthcare and inconsistent feeding
oversight by HCPs.37

LIMITATIONS

The largest limitation was the small sample size. This study
was partially conducted during the COVID-19 pandemic,
which severely impacted the ability to recruit and maintain
participation. Inconsistent access to patients and variable
outcomes (hospitalization, death, or discontinu-
ance of tube feeding) are difficulties reported in the oncology
outpatient clinics treating the HNC population.25,33
Additionally, depending on the treatment regimen and the
physical frailties of the patients, some anthropometric and
survey data were not able to be collected. Frequently,
consultations with the RDNs working in the clinic occurred
around chemotherapy infusion or radiation treatments,
and measurements/survey data were not feasible. A fur-
ther limitation encountered was in the physical frailties of
patients as a result of their diagnoses/treatment that made it
difficult for them to stand for anthropometric mea-

CONCLUSIONS

Although the results of this pilot study are not generaliz-
able, they do support existing papers on the efficacy of BTF
in children and adults. This investigation and the one by
Hurt et al are of particular importance because, in both,
weight loss and declining QOL scores typical of weeks
3–4 in HNC chemoradiation therapy were reversed with the
addition of BTF.35 Despite the difficulties of conduct-
ing larger trials in the HNC patient population, they are
needed to further investigate the efficacy of BTF in a pop-
ulation that may benefit at a critical moment in their care.

CONFLICT OF INTERESTS

Ryan T. Hurt is a consultant for Nestlé Nutrition and Lisa
Epp is a consultant for Abbott Nutrition, Nestlé Nutrition,
and Halyard Avanos. Manpreet S. Mundi has received
research grant funding from Nestlé, Fresenius Kabi, and
Real Food Blends. All others report no conflicts.

AUTHOR CONTRIBUTIONS

Amy Y. Spurlock, Teresa W. Johnson, Ali Pritchett, Leah
Pierce, Jenna Hussey, Kelly Johnson, Holly Carter, Stephen
L. Davidson, Manpreet S. Mundi, Lisa Epp, and Ryan T.
Hurt equally contributed to the conception and design of
the research; Amy Y. Spurlock, Teresa W. Johnson, Ali
Pritchett, and Leah Pierce contributed to the design of the
research; Ali Pritchett, Leah Pierce, Amy Y. Spurlock, and
Teresa W. Johnson contributed to the acquisition and anal-
ysis of the data; Amy Y. Spurlock and Teresa W. Johnson
contributed to the interpretation of the data; and Amy Y.
Spurlock and Teresa W. Johnson drafted the manuscript.
All authors critically revised the manuscript, agree to be
fully accountable for ensuring the integrity and accuracy
of the work, and read and approved the final manuscript.

Acknowledgements: The authors wish to acknowledge
the contributions of Taylor Carbone and Sydney Elston
(Troy University, Troy, Alabama) in the completion of this

ORCID

Teresa W. Johnson DCN, RDN @ https://orcid.org/0000-
0002-5299-900X
Manpreet S. Mundi MD @ https://orcid.org/0000-0001-
7902-3544

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer
   J Clin. 2019;69(1):7-34.
2. Nagai H, Kim YH. Cancer prevention from the perspective of
global cancer burden patterns. J Thorac Dis. 2017;9(3):448-451.
3. Thompson-Harvey A, Yetukuri M, Hansen AR, et al. Rising inci-
dence of late-stage head and neck cancer in the United States.
Cancer. 2020;126(5):1090-1101.
4. Raykher A, Russo L, Schattner M, Schwartz L, Scott B, Shike M.
Enteral nutrition support of head and neck cancer patients. Nutr
Clin Pract. 2007;22(1):68-73.
5. Locher JL, Bonner JA, Carroll WR, et al. Prophylactic percu-
taneous endoscopic gastrostomy tube placement in treatment
of head and neck cancer: a comprehensive review and call
for evidence-based medicine. JPN J Parenter Enteral Nutr.
2011;35(3):365-374.
6. Mulasi U, Vock DM, Jager-Wittenaar H, et al. Nutrition sta-
tus and health-related quality of life among outpatients with
advanced head and neck cancer. Nutr Clin Pract. 2020;35(6):1129-
1137.
7. Lu Y, Carey S. Translating evidence-based practice guidelines
into a summary of recommendations for the nutrition manage-
ment of upper gastrointestinal cancers. Nutr Clin Pract.
2014;29(4):518-525.
8. Arends J, Baracos V, Bertz H, et al. ESPEN expert group recom-
endations for action against cancer-related malnutrition. Clin
Nutr. 2017;36(5):1187-1196.
9. Nunes G, Fonseca J, Barata AT, Dinis-Ribeiro M, Pin-
entel-Nunes P. Nutritional support of cancer patients
without oral feeding: how to select the most effective tech-
teque? GE Port J Gastroenterol. 2020;27(3):172-184.
10. Brown TE, Banks MD, Hughes BGM, Lin CY, Kenny LM, Bauer
JD. Randomised controlled trial of early prophylactic feeding vs
standard care in patients with head and neck cancer. Br J Cancer.
2017;117(1):15-24.
11. Bossola M. Nutritional interventions in head and neck cancer patients undergoing chemoradiotherapy: a narrative review. *Nutrients*. 2015;7(1):265-276.

12. Coad J, Toft A, Lapwood S, et al. Blended foods for tube-fed children: a safe and realistic option? A rapid review of the evidence. *Arch Dis Child*. 2017;102:274-278.

13. Carter H, Johnson K, Johnson TW, Spurlock A. Blended tube feeding prevalence, efficacy, and safety: what does the literature say? *J Am Assoc Nur Pract*. 2018;30(3):150-157.

14. Kariya C, Bell K, Bellamy C, Lau J, Yee K. Blenderized tube feeding: a survey of dietitians’ perspectives, education, and perceived competence. *Can J Diet Pract Res*. 2019;80(4):190-194.

15. Johnson T, Spurlock A, Epp L, Hurt RT, Mundi MS. Reemergence of blended tube feeding and parent’s reported experiences in their tube fed children. *J Alt Com Med*. 2018;24(4):369-373.

16. Epp L, Lammert L, Vallumsetla N, Hurt RT, Mundi M. Use of blended tube feeding in chronic illness tube-fed children. *Nutr Clin Pract*. 2011;35(3):375-379.

17. Hurt RT, Edakkamambeth VJ, Epp L, et al. Blenderized tube feeding use in adult home enteral nutrition patients: a cross-sectional study. *Nutr Clin Pract*. 2015;30(6):824-829.

18. Hron B, Fishman E, Lurie M, et al. Health outcomes and quality of life indices of children receiving blended feeds via enteral tube. *J Pediatr*. 2019;211:139-145.

19. Armstrong J, Buchanan E, Duncan H, Ross K, Gerasimidis K. Dietitians’ perceptions and experience of blended feeds for paediatric tube-feeding. *Arch Dis Child*. 2016;102(2):152-156.

20. Johnson TW, Spurlock A, Pierce L. Survey study assessing attitudes and experiences of pediatric registered dietitians regarding blended food by gastrostomy tube feeding. *Nutr Clin Pract*. 2015;30(3):402-405.

21. Pentiu S, O’Flaherty T, Santoro K, Willging P, Kaul A. Pureed by gastrostomy tube diet improves gagging and retching in children with fundoplication. *JPEN J Parenter Enteral Nutr*. 2011;35(3):375-379.

22. Batsis I, Davis L, Pritchett L, et al. Efficacy and tolerance of blended diets in children receiving gastrostomy feeds. *Nutr Clin Pract*. 2020;35(2):282-288.

23. McClanahan D, Yeh A, Ferek B, et al. Pilot study of the effect of plant-based enteral nutrition on the gut microbiota in chronically ill tube-fed children. *JPEN J Parenter Enteral Nutr*. 2019;43(7):899-911.

24. Gallagher K, Flint A, Mouzaki M, et al. Blenderized enteral nutrition diet study: feasibility, clinical, and microbiome outcomes of providing blendedized feeds through a gastric tube in a medically complex pediatric population. *JPEN J Parenter Enteral Nutr*. 2018;42(6):1046-1060.

25. Hurt RT, Epp LM, Duellman WM, et al. Blenderized tube feedings for adult patients on home enteral nutrition: a pilot study. *J Altern Complement Med*. 2019;25(4):413-416.

26. Fabiani A, Sanson G, Bottigliengo D, et al. Impact of a natural versus commercial enteral-feeding on the occurrence of diarrhea in critically ill cardiac surgery patients. A retrospective cohort study. *Int J Nurs Stud*. 2020;108:103605.

27. Schmidt SB, Kulig W, Winter R, Vasold AS, Knoll AE, Rollnik JD. The effect of a natural food based tube feeding in minimizing diarrhea in critically ill neurological patients. *Clin Nutr*. 2019;38(1):332-340.

28. Pritchett A, Pierce L, Kiser S, Johnson TW, Barrows N. Blenderized food tube feeding for radioactive iodine ablation: a case presentation and review of the literature. *Top Clin Nutr*. 2021;36(2):177-185.

29. Papakostas P, Tsouios G, Stavrou G, et al. Percutaneous endoscopic gastrostomy feeding of locally advanced oro-pharyngeal cancer patients: blended or commercial food? *Otol Oncol*. 2017;74:135-141.

30. White JV, Guenter P, Jensen G, et al. Consensus statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). *J Acad Nutr Diet*. 2012;112(5):730-738.

31. Pandit P, Patil R, Palwe V, Yasam VR, Nagarkar R. Predictors of weight loss in patients with head and neck cancer receiving radiation or concurrent chemoradiation treated at a tertiary cancer center. *Nutr Clin Pract*. 2020;35(6):1047-1052.

32. Langius JA, Bakker S, Rietveld DH, et al. Critical weight loss is a major prognostic indicator for disease-specific survival in patients with head and neck cancer receiving radiotherapy. *Br J Cancer*. 2013;109(5):1093-1099.

33. Mulasli U, Vock DM, Jager-Wittenaar H, et al. Nutrition status and health-related quality of life among outpatients with advanced head and neck cancer. *Nutr Clin Pract*. 2020;35(6):1129-1137.

34. World Cancer Research Fund, American Institute for Cancer Research. Diet, nutrition, physical activity and cancer: a global perspective. Continuous update project expert report 2018. Accessed March 4, 2021. https://www.wcrf.org/sites/default/files/Summary-of-Third-Expert-Report-2018.pdf.

35. Schwedhelm C, Boeig H, Hoffmann G, Alekandrova K, Schwinghackle L. Effect of diet on mortality and cancer recurrence among cancer survivors: a systematic review and meta-analysis of cohort studies. *Nutr Rev*. 2016;74(12):737-748.

36. Lee E, Zhu J, Velazquez J, et al. Evaluation of diet quality among American adult cancer survivors: results from 2005–2016 National Health and Nutrition Examination Survey. *J Acad Nutr Diet*. 2021;121(2):217-232.

37. Bennett K, Hjelmgren B, Piazza J. Blenderized tube feeding: health outcomes and review of homemade and commercially prepared products. *Nutr Clin Pract*. 2020;35(3):417-431.

38. Milton DL, Johnson TW, Johnson K, et al. Accepted safe food-handling procedures minimizes microbial contamination of home-prepared blendedized tube-feeding. *Nutr Clin Pract*. 2020;35(3):479-486.

39. Johnson TW, Milton DL, Johnson K, et al. Comparison of microbial growth between commercial formula and blendedized food for tube feeding. *Nutr Clin Pract*. 2019;34(2):257-263.

**How to cite this article:** Spurlock AY, Johnson TW, Pritchett A, et al. Blenderized food tube feeding in patients with head and neck cancer. *Nutrition in Clinical Practice*. 2022;37:615–624. https://doi.org/10.1002/ncp.10760